Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
FFP transfusion
plasma derivatives
transfusion-transmitted disease-other
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
03
11
2021
received:
13
03
2021
accepted:
15
11
2021
pubmed:
8
2
2022
medline:
25
3
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
COVID-19 convalescent plasma (CCP), from donors recovered from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is one of the limited therapeutic options currently available for the treatment of critically ill patients with COVID-19. There is growing evidence that CCP may reduce viral loads and disease severity; and reduce mortality. However, concerns about the risk of transfusion-transmitted infections (TTI) and other complications associated with transfusion of plasma, remain. Amotosalen/UVA pathogen reduction treatment (A/UVA-PRT) of plasma offers a mitigation of TTI risk, and when combined with pooling has the potential to increase the diversity of the polyclonal SARS-CoV-2 neutralizing antibodies. This study assessed the impact of A/UVA-PRT on SARS-CoV-2 antibodies in 42 CCP using multiple complimentary assays including antigen binding, neutralizing, and epitope microarrays. Other mediators of CCP efficacy were also assessed. A/UVA-PRT did not negatively impact antibodies to SARS-CoV-2 and other viral epitopes, had no impact on neutralizing activity or other potential mediators of CCP efficacy. Finally, immune cross-reactivity with other coronavirus antigens was observed raising the potential for neutralizing activity against other emergent coronaviruses. The findings of this study support the selection of effective CCP combined with the use of A/UVA-PRT in the production of CCP for patients with COVID-19.
Sections du résumé
BACKGROUND
COVID-19 convalescent plasma (CCP), from donors recovered from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is one of the limited therapeutic options currently available for the treatment of critically ill patients with COVID-19. There is growing evidence that CCP may reduce viral loads and disease severity; and reduce mortality. However, concerns about the risk of transfusion-transmitted infections (TTI) and other complications associated with transfusion of plasma, remain. Amotosalen/UVA pathogen reduction treatment (A/UVA-PRT) of plasma offers a mitigation of TTI risk, and when combined with pooling has the potential to increase the diversity of the polyclonal SARS-CoV-2 neutralizing antibodies.
STUDY DESIGN AND METHODS
This study assessed the impact of A/UVA-PRT on SARS-CoV-2 antibodies in 42 CCP using multiple complimentary assays including antigen binding, neutralizing, and epitope microarrays. Other mediators of CCP efficacy were also assessed.
RESULTS
A/UVA-PRT did not negatively impact antibodies to SARS-CoV-2 and other viral epitopes, had no impact on neutralizing activity or other potential mediators of CCP efficacy. Finally, immune cross-reactivity with other coronavirus antigens was observed raising the potential for neutralizing activity against other emergent coronaviruses.
CONCLUSION
The findings of this study support the selection of effective CCP combined with the use of A/UVA-PRT in the production of CCP for patients with COVID-19.
Identifiants
pubmed: 35128658
doi: 10.1111/trf.16819
pmc: PMC9115453
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Furocoumarins
0
amotosalen
K1LDZ0VBC0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
570-583Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
Nat Commun. 2021 Jan 4;12(1):6
pubmed: 33397903
Rev Med Virol. 2020 Jul;30(4):e2112
pubmed: 32502331
Transfusion. 2020 May;60(5):1024-1031
pubmed: 32129478
Nat Commun. 2020 Sep 17;11(1):4698
pubmed: 32943630
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
SLAS Technol. 2020 Dec;25(6):545-552
pubmed: 32815769
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Anesth Analg. 2011 Jun;112(6):1289-95
pubmed: 21346161
Am J Pathol. 2020 Nov;190(11):2290-2303
pubmed: 32795424
Antiviral Res. 2008 Apr;78(1):132-9
pubmed: 18054395
Kidney Int. 2020 Aug;98(2):509-512
pubmed: 32525010
Pathog Glob Health. 2020 Mar;114(2):64-67
pubmed: 32048560
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
Clin Chim Acta. 2020 Oct;509:280-287
pubmed: 32531256
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Lancet. 1984 Aug 4;2(8397):255-6
pubmed: 6146809
Thromb Res. 2020 Sep;193:170-172
pubmed: 32707276
ACS Cent Sci. 2016 Mar 23;2(3):139-147
pubmed: 27064772
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Vox Sang. 2013 Apr;104(3):183-99
pubmed: 23134556
Br J Haematol. 2020 Jun;189(6):e227-e230
pubmed: 32369610
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91
pubmed: 16172857
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
J Virol Methods. 2013 Feb;187(2):362-7
pubmed: 23178532
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
J Immunol. 2020 Sep 15;205(6):1488-1495
pubmed: 32699160
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Lab Chip. 2020 Sep 21;20(18):3302-3309
pubmed: 32743622
J Med Virol. 2020 Jun;92(6):667-674
pubmed: 32167180
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
J Immunol Methods. 2020 Nov;486:112837
pubmed: 32828791
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
Transfusion. 2022 Mar;62(3):570-583
pubmed: 35128658
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443
pubmed: 32307245
Nat Microbiol. 2020 Jun;5(6):796-812
pubmed: 32367055
Biomed Res Int. 2016;2016:7870590
pubmed: 26925413
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803
Transfusion. 2020 Jun;60(6):1319-1331
pubmed: 32333396
Genes Dis. 2020 Dec;7(4):551-557
pubmed: 32837985
Biochim Biophys Acta. 2007 Jul;1772(7):788-96
pubmed: 17499484
J Neuroinflammation. 2018 Dec 12;15(1):342
pubmed: 30541566
Curr Hypertens Rep. 2020 Aug 27;22(9):63
pubmed: 32852642
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620933945
pubmed: 32619104